does pfizer make a glp-1 to discontinue danuglipron, its pill for obesity| STAT Pfizer's Bold Move in the

Both Mounjaro and Zepbound feature tirzepatide, a dual agonist for GLP-1 and GIP receptors

For patients looking to shed 10-20 pounds or fine-tune their body composition, microdosing may provide sufficient metabolic support without the intensity of full-dose protocols

If these drugs truly help prevent or reduce substance use disorders, the impact could be significant at the population level

First, digestion redirects blood flow from the oral mucosa to the GI tract, reducing the efficiency of sublingual uptake

This is why consultation and individualized planning are essential, as rushing treatment too early can limit outcomes